1. Home
  2. STTK vs RMNI Comparison

STTK vs RMNI Comparison

Compare STTK & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.53

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Logo Rimini Street Inc. (DE)

RMNI

Rimini Street Inc. (DE)

N/A

Current Price

$5.22

Market Cap

383.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
RMNI
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
383.7M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
STTK
RMNI
Price
$4.53
$5.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
3
Target Price
★ $15.40
$7.17
AVG Volume (30 Days)
★ 841.6K
509.7K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
★ 197.50
EPS
N/A
★ 0.11
Revenue
$1,000,000.00
★ $431,496,000.00
Revenue This Year
N/A
$5.92
Revenue Next Year
$14.28
$5.90
P/E Ratio
★ N/A
$49.45
Revenue Growth
N/A
★ 5.33
52 Week Low
$1.89
$2.87
52 Week High
$8.33
$5.68

Technical Indicators

Market Signals
Indicator
STTK
RMNI
Relative Strength Index (RSI) 36.65 59.44
Support Level $4.38 $3.17
Resistance Level $7.66 $5.68
Average True Range (ATR) 0.39 0.29
MACD -0.02 0.01
Stochastic Oscillator 13.92 59.26

Price Performance

Historical Comparison
STTK
RMNI

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About RMNI Rimini Street Inc. (DE)

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.

Share on Social Networks: